



\$140 Million
Follow-On Offering



Joint Bookrunner
January 2024

Leerink Partners Serves as Joint Bookrunner for Keros Therapeutics' (Nasdaq: KROS) \$140 Million Follow-On Offering

Key Transaction Highlights

- Confidentially marketed deal that publicly launched and priced on January 3rd.
- Base deal upsized from \$120 million to \$140 million.
- Consisted of 3,500,000 shares of common stock at a price of \$40.00 per share, representing a 3.1% discount to the last sale price
- Keros intends to use the net proceeds of this offering, together with its existing cash and cash equivalents, to continue to advance the development of KER-050 in two Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis, and to initiate one Phase 3 clinical trial; to continue the development of KER-012 in two Phase 2 clinical trials, one in patients with PAH and one in patients with chronic heart failure with preserved ejection fraction and in such patients with reduced ejection fraction; to advance the development of KER-065, including the completion of the ongoing Phase 1 clinical trial; and to continue the development of its preclinical pipeline; Keros intends to use the remainder, if any, to fund other research and development activities, including activities related to its proprietary discovery approach, for working capital and for general corporate purposes.
- This is Leerink Partners' 3rd equity offering for Keros Therapeutics and 1st equity offering in 2024.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

MIAMI
1395 Brickell Avenue
Suite 800
Miami, FL 33131

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111